Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Trifluoperazine hydrochloride
Drug ID BADD_D02282
Description A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.
Indications and Usage For the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.
Marketing Status approved; investigational
ATC Code N05AB06
DrugBank ID DB00831
KEGG ID D00799
MeSH ID D014268
PubChem ID 66064
TTD Drug ID D0R4OM
NDC Product Code 0781-8032; 51079-572; 0378-2410; 51079-573; 0378-2405; 0781-8034; 46204-0081; 0781-8028; 0781-8036; 70518-2095; 51079-574; 0378-2402; 51079-575; 0378-2401; 70518-2106
UNII 6P1Y2SNF5V
Synonyms Trifluoperazine | Trifluperazine | Trifluoroperazine | Eskazine | Flupazine | Terfluzine | Trifluoperazine Hydrochloride | Trifluoperazine HCL | Triftazin | Apo-Trifluoperazine | Apo Trifluoperazine | ApoTrifluoperazine | Stelazine
Chemical Information
Molecular Formula C21H26Cl2F3N3S
CAS Registry Number 440-17-5
SMILES CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F.Cl.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Neuroleptic malignant syndrome15.05.04.015; 12.03.01.003; 08.05.01.005; 17.05.02.003--Not Available
Oculogyric crisis17.01.03.002; 06.05.02.002--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Opisthotonus17.01.03.005--Not Available
Pancytopenia01.03.03.003--Not Available
Parkinsonism17.01.05.003--Not Available
Photosensitivity reaction23.03.09.003--
Pregnancy test false positive13.10.05.003--Not Available
Priapism24.04.12.007; 21.03.01.005--Not Available
Protrusion tongue17.02.05.037; 07.14.02.002--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Retinal dystrophy06.09.03.012--Not Available
Seizure17.12.03.001--
Skin disorder23.03.03.007--Not Available
Skin reaction23.03.03.013; 10.01.03.019--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Swelling face08.01.03.100; 23.04.01.018; 10.01.05.018--Not Available
Systemic lupus erythematosus10.04.03.004; 23.03.02.006; 15.06.02.003--Not Available
Tardive dyskinesia17.01.02.012--Not Available
Throat tightness22.12.03.031; 19.01.02.005--Not Available
Thrombocytopenic purpura23.06.01.007; 01.08.01.003--Not Available
Tremor17.01.06.002--
Urticaria10.01.06.001; 23.04.02.001--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Brain oedema17.07.02.003; 12.01.10.010--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages